Articles

According to the company, the trial did not demonstrate efficacy on the key clinical endpoints. As a result, Oxurion will now shift its focus to the Phase 2 development program for THR-149, which recently demonstrated a compelling safety and efficacy profile for the treatment of DME.

Phase 2 INTEGRAL trial: THR-689 fails to meet primary endpoints in eyes with DME, will not advance

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of 

Treatments include tinted spectacles and/or contact lenses, low-vision aids, atropine drops, and patching for amblyopia, as well as eye muscle surgery for the nystagmus or any anomalous head posture and associated strabismus.

Novel oculomotor characteristics of achromatopsia

According to an e-poster presented by Jagadesh C. Reddy, MD, and Harini Indusekar, BScOptom, at the ASCRS in Washington, D.C., patients who have pre-existing DR are less likely to achieve Snellen 20/40 or better vison after cataract surgery compared with the patients with diabetes but without DR.

Diabetic retinopathy's effect on early visual outcomes after cataract surgery

The data presented at ARVO showed single subcutaneous doses of D-4517.2 were safe, well-tolerated in healthy subjects.

Phase 1 safety data for subcutaneous anti-VEGF candidate for wet AMD, DME presented at ARVO

According to the ALOFT study, patients demonstrate improved long-term vision in real-world setting after wet AMD conversion compared to current standard of care.

AMD remote monitoring improves outcomes for patients, retrospective study shows

The Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Colorado, revealed a variety of advancements in technology, pivotal trials and clinical trial design.

ARVO 2022 recap: A review of data and innovation at the annual meeting

Videos

Jennifer I. Lim, MD, FARVO, FASRS, reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular edema.

2-year results of YOSEMITE and RHINE: Faricimab remains noninferior to aflibercept with extended dosing schedule

Poll

Results from our recent poll regarding Retina World Congress 2022 attendance indicate that while many retina specialists will attend the Congress, the majority will not be in Fort Lauderdale, Florida.

Poll results: Are you attending Retina World Congress 2022?

The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.

Phase 3 PEACHTREE, AZALEA integrated study results: BCVA gains, CST reduction associated with suprachoirodal injection

Dr. Diana Do presents data on a novel patient-reported outcome instrument for patients with proliferative diabetic retinopathy with the hope of capturing the burden of the disease and treatment.

Poll results: Are you attending Retina World Congress 2022?

Phase 3 PEACHTREE, AZALEA integrated study results: BCVA gains, CST reduction associated with suprachoirodal injection

Capturing the treatment burden of diabetic retinopathy with novel PRO instrument